Best Stocks Under $3 | Low-Priced Stocks for $3 or Less

1. Ur Energy NYSEAMERICAN:URG

$1.06 -0.02 (-1.85%)

Closing price 04:10 PM Eastern

Extended Trading

$1.08 +0.02 (+2.08%)

As of 06:21 PM Eastern

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization: $421.23 million
Consensus Rating: Buy
Consensus Price Target: $2.28 (+115.1% Upside)
Volume: 6.70 million shares
Average Volume: 9.11 million shares
Today's Range: $1.05
▼
$1.10

2. iBio NASDAQ:IBIO

$1.11 -0.07 (-5.93%)

Closing price 04:00 PM Eastern

Extended Trading

$1.13 +0.02 (+1.80%)

As of 05:55 PM Eastern

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBio

Market Capitalization: $71.38 million
Consensus Rating: Buy
Consensus Price Target: $5.29 (+376.2% Upside)
Volume: 337,887 shares
Average Volume: 1.12 million shares
Today's Range: $1.10
▼
$1.21

3. Nouveau Monde Graphite NYSE:NMG

$1.18 -0.03 (-2.08%)

Closing price 03:59 PM Eastern

Extended Trading

$1.20 +0.02 (+2.13%)

As of 05:29 PM Eastern

Nouveau Monde Graphite Inc engages in the acquisition, exploration, development, and evaluation of mineral properties in Quebec, Canada. More about Nouveau Monde Graphite

Market Capitalization: $386.76 million
Consensus Rating: Buy
Consensus Price Target: $3.87 (+229.4% Upside)
Volume: 519,197 shares
Average Volume: 844,706 shares
Today's Range: $1.16
▼
$1.20

4. Stereotaxis NYSEAMERICAN:STXS

$1.20 -0.03 (-2.44%)

Closing price 04:10 PM Eastern

Extended Trading

$1.24 +0.04 (+2.92%)

As of 05:59 PM Eastern

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about Stereotaxis

Market Capitalization: $120.24 million
Consensus Rating: Buy
Consensus Price Target: $3.50 (+191.7% Upside)
Volume: 671,522 shares
Average Volume: 593,086 shares
Today's Range: $1.18
▼
$1.24

5. Galiano Gold NYSEAMERICAN:GAU

$1.95 +0.01 (+0.52%)

Closing price 04:10 PM Eastern

Extended Trading

$1.97 +0.02 (+0.92%)

As of 05:34 PM Eastern

Galiano Gold Inc engages in the exploration and evaluation of gold properties in Canada. Its flagship asset is the Asanko Gold Mine that covers an area of approximately 21,000 hectares located in Ghana, West Africa. More about Galiano Gold

Market Capitalization: $509.98 million
P/E Ratio: 7.50
Consensus Rating: Buy
Consensus Price Target: $4.25 (+117.9% Upside)
Volume: 1.77 million shares
Average Volume: 3.24 million shares

6. Niagen Bioscience NASDAQ:NAGE

$2.68 -0.24 (-8.22%)

Closing price 04:00 PM Eastern

Extended Trading

$2.69 +0.01 (+0.30%)

As of 06:09 PM Eastern

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. More about Niagen Bioscience

Market Capitalization: $213.44 million
P/E Ratio: 14.89
Consensus Rating: Buy
Consensus Price Target: $10.33 (+285.6% Upside)
Volume: 1.38 million shares
Average Volume: 874,755 shares

7. Inhibikase Therapeutics NASDAQ:IKT

$1.93 -0.13 (-6.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 +0.01 (+0.26%)

As of 05:52 PM Eastern

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase Therapeutics

Market Capitalization: $269.31 million
Consensus Rating: Buy
Consensus Price Target: $5.40 (+179.8% Upside)
Volume: 474,644 shares
Average Volume: 1.12 million shares
Today's Range: $1.93
▼
$2.10

8. Palisade Bio NASDAQ:PALI

$1.43 +0.08 (+5.93%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 0.00 (-0.35%)

As of 05:47 PM Eastern

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More about Palisade Bio

Market Capitalization: $249.21 million
Consensus Rating: Buy
Consensus Price Target: $9.83 (+587.6% Upside)
Volume: 2.64 million shares
Average Volume: 3.66 million shares
Today's Range: $1.37
▼
$1.46

9. Perspective Therapeutics NYSEAMERICAN:CATX

$2.72 -0.03 (-1.09%)

Closing price 04:10 PM Eastern

Extended Trading

$2.74 +0.02 (+0.70%)

As of 06:20 PM Eastern

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective Therapeutics

Market Capitalization: $310.49 million
Consensus Rating: Buy
Consensus Price Target: $11.50 (+322.8% Upside)
Volume: 1.54 million shares
Average Volume: 2.23 million shares
Today's Range: $2.66
▼
$2.78

10. Compugen NASDAQ:CGEN

$2.34 -0.04 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$2.35 +0.01 (+0.56%)

As of 06:16 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. More about Compugen

Market Capitalization: $221.25 million
P/E Ratio: 6.16
Consensus Rating: Buy
Consensus Price Target: $5.00 (+113.7% Upside)
Volume: 173,346 shares
Average Volume: 375,424 shares

11. Equillium NASDAQ:EQ

$1.54 -0.09 (-5.23%)

Closing price 04:00 PM Eastern

Extended Trading

$1.59 +0.05 (+3.44%)

As of 06:12 PM Eastern

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More about Equillium

Market Capitalization: $97.65 million
Consensus Rating: Moderate Buy
Consensus Price Target: $7.57 (+391.7% Upside)
Volume: 528,972 shares
Average Volume: 622,035 shares
Today's Range: $1.53
▼
$1.67

12. Ovid Therapeutics NASDAQ:OVID

$2.43 -0.06 (-2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.45 +0.02 (+0.86%)

As of 05:06 PM Eastern

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization: $474.58 million
Consensus Rating: Moderate Buy
Consensus Price Target: $6.00 (+146.9% Upside)
Volume: 1.35 million shares
Average Volume: 2.34 million shares
Today's Range: $2.42
▼
$2.53

13. Prime Medicine NASDAQ:PRME

$2.99 -0.07 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$3.01 +0.02 (+0.54%)

As of 06:22 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. More about Prime Medicine

Market Capitalization: $542.33 million
Consensus Rating: Moderate Buy
Consensus Price Target: $7.47 (+149.9% Upside)
Volume: 2.83 million shares
Average Volume: 2.95 million shares
Today's Range: $2.98
▼
$3.11

14. Cabaletta Bio NASDAQ:CABA

$1.89 -0.03 (-1.56%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 +0.03 (+1.80%)

As of 06:10 PM Eastern

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More about Cabaletta Bio

Market Capitalization: $320.43 million
Consensus Rating: Moderate Buy
Consensus Price Target: $15.33 (+711.3% Upside)
Volume: 8.53 million shares
Average Volume: 4.10 million shares
Today's Range: $1.86
▼
$1.97

15. Autolus Therapeutics NASDAQ:AUTL

$1.85 -0.09 (-4.64%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 +0.00 (+0.27%)

As of 05:34 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus Therapeutics

Market Capitalization: $492.40 million
Consensus Rating: Moderate Buy
Consensus Price Target: $10.00 (+440.5% Upside)
Volume: 1.42 million shares
Average Volume: 1.79 million shares
Today's Range: $1.85
▼
$1.94

16. Canaan NASDAQ:CAN

$0.34 -0.01 (-1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.34 +0.00 (+0.88%)

As of 06:20 PM Eastern

Canaan Inc engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. More about Canaan

Market Capitalization: $243.51 million
Consensus Rating: Moderate Buy
Consensus Price Target: $1.75 (+414.7% Upside)
Volume: 6.96 million shares
Average Volume: 13.64 million shares
Today's Range: $0.33
▼
$0.36

17. Nkarta NASDAQ:NKTX

$2.56 -0.06 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 0.00 (-0.20%)

As of 05:36 PM Eastern

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about Nkarta

Market Capitalization: $183.35 million
Consensus Rating: Moderate Buy
Consensus Price Target: $11.20 (+337.5% Upside)
Volume: 402,297 shares
Average Volume: 726,311 shares
Today's Range: $2.55
▼
$2.67

18. Tenaya Therapeutics NASDAQ:TNYA

$0.57 -0.04 (-6.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.57 +0.01 (+1.29%)

As of 06:09 PM Eastern

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya Therapeutics

Market Capitalization: $126.85 million
Consensus Rating: Moderate Buy
Consensus Price Target: $4.00 (+607.1% Upside)
Volume: 4.74 million shares
Average Volume: 3.45 million shares
Today's Range: $0.56
▼
$0.60

19. Gold Royalty NYSEAMERICAN:GROY

$2.99 -0.01 (-0.33%)

Closing price 04:10 PM Eastern

Extended Trading

$2.99 0.00 (-0.13%)

As of 05:43 PM Eastern

Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. More about Gold Royalty

Market Capitalization: $690.12 million
P/E Ratio: 299.30
Consensus Rating: Moderate Buy
Consensus Price Target: $5.64 (+88.7% Upside)
Volume: 1.73 million shares
Average Volume: 2.48 million shares

20. Denison Mine NYSEAMERICAN:DNN

$2.54 -0.05 (-1.93%)

Closing price 04:10 PM Eastern

Extended Trading

$2.55 +0.01 (+0.35%)

As of 06:21 PM Eastern

Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison Mine

Market Capitalization: $2.30 billion
Consensus Rating: Moderate Buy
Consensus Price Target: $5.38 (+111.6% Upside)
Volume: 17.49 million shares
Average Volume: 32.56 million shares
Today's Range: $2.52
▼
$2.61

21. NervGen Pharma NASDAQ:NGEN

$1.76 -0.15 (-7.85%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 +0.10 (+5.74%)

As of 06:21 PM Eastern

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. More about NervGen Pharma

Market Capitalization: $141.91 million
Consensus Rating: Moderate Buy
Consensus Price Target: $14.00 (+695.5% Upside)
Volume: 1.05 million shares
Average Volume: 511,589 shares
Today's Range: $1.73
▼
$1.92

22. CytomX Therapeutics NASDAQ:CTMX

$2.63 -0.09 (-3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$2.69 +0.06 (+2.28%)

As of 05:42 PM Eastern

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More about CytomX Therapeutics

Market Capitalization: $573.08 million
Consensus Rating: Moderate Buy
Consensus Price Target: $11.90 (+352.5% Upside)
Volume: 2.70 million shares
Average Volume: 4.79 million shares
Today's Range: $2.62
▼
$2.78

23. Rani Therapeutics NASDAQ:RANI

$0.80 +0.00 (+0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$0.79 0.00 (-0.57%)

As of 05:43 PM Eastern

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani Therapeutics

Market Capitalization: $110.89 million
Consensus Rating: Moderate Buy
Consensus Price Target: $8.75 (+999.9% Upside)
Volume: 484,035 shares
Average Volume: 942,525 shares
Today's Range: $0.79
▼
$0.85

24. Entera Bio NASDAQ:ENTX

$2.89 -0.02 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$2.90 +0.01 (+0.35%)

As of 04:10 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. More about Entera Bio

Market Capitalization: $502.63 million
Consensus Rating: Moderate Buy
Consensus Price Target: $9.60 (+232.2% Upside)
Volume: 640,826 shares
Average Volume: 1.02 million shares
Today's Range: $2.81
▼
$3.00

25. AEON Biopharma NASDAQ:AEON

$0.29 -0.01 (-3.33%)

Closing price 04:00 PM Eastern

Extended Trading

$0.29 +0.00 (+1.03%)

As of 06:22 PM Eastern

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. More about AEON Biopharma

Market Capitalization: $14.47 million
P/E Ratio: 1.61
Consensus Rating: Moderate Buy
Consensus Price Target: $1.67 (+474.7% Upside)
Volume: 6.59 million shares
Average Volume: 2.94 million shares

Best Stocks Under $3 Right Now

1. Ur Energy NYSEAMERICAN:URG

2. iBio NASDAQ:IBIO

3. Nouveau Monde Graphite NYSE:NMG

4. Stereotaxis NYSEAMERICAN:STXS

5. Galiano Gold NYSEAMERICAN:GAU

6. Niagen Bioscience NASDAQ:NAGE

7. Inhibikase Therapeutics NASDAQ:IKT

8. Palisade Bio NASDAQ:PALI

9. Perspective Therapeutics NYSEAMERICAN:CATX

10. Compugen NASDAQ:CGEN

11. Equillium NASDAQ:EQ

12. Ovid Therapeutics NASDAQ:OVID

13. Prime Medicine NASDAQ:PRME

14. Cabaletta Bio NASDAQ:CABA

15. Autolus Therapeutics NASDAQ:AUTL

16. Canaan NASDAQ:CAN

17. Nkarta NASDAQ:NKTX

18. Tenaya Therapeutics NASDAQ:TNYA

19. Gold Royalty NYSEAMERICAN:GROY

20. Denison Mine NYSEAMERICAN:DNN

21. NervGen Pharma NASDAQ:NGEN

22. CytomX Therapeutics NASDAQ:CTMX

23. Rani Therapeutics NASDAQ:RANI

24. Entera Bio NASDAQ:ENTX

25. AEON Biopharma NASDAQ:AEON

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Best Stocks Under $3 Right Now

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools